Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Titan Pharmaceuticals, Inc. (TTNP) had Return on Tangible Equity of -192.87% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-4.71M |
|
-- |
|
-- |
|
$4.56M |
|
$-4.56M |
|
$-0.15M |
|
$-4.71M |
|
$-4.71M |
|
$-4.71M |
|
$-4.71M |
|
$-4.71M |
|
$-4.71M |
|
$-4.56M |
|
$-4.55M |
|
0.90M |
|
0.90M |
|
$-5.23 |
|
$-5.23 |
|
| Balance Sheet Financials | |
$2.92M |
|
-- |
|
-- |
|
$2.92M |
|
$0.48M |
|
-- |
|
-- |
|
$0.48M |
|
$2.44M |
|
$2.44M |
|
$2.44M |
|
0.91M |
|
| Cash Flow Statement Financials | |
$-3.88M |
|
-- |
|
$-0.06M |
|
$6.77M |
|
$2.83M |
|
$-3.94M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.05 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-3.88M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-192.95% |
|
|
Return on Tangible Equity |
-192.87% |
-161.00% |
|
-192.87% |
|
$2.67 |
|
$-4.32 |
|
$-4.32 |
|